All the news Showing 10 of 130 articles from: TreatmentGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Are New Drugs for Hepatitis C Safe? A Report Raises Concerns New York Times / 25 January 2017 Tenofovir alafenamide approved for hepatitis B in Europe Liz Highleyman / 16 January 2017 The European Commission this week granted marketing authorisation for tenofovir alafenamide, to be sold under the brand name Vemlidy, for the treatment of chronic hepatitis B virus (HBV) infection, according ... European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection Gilead press release / 11 January 2017 GS-4774 therapeutic vaccine shows little efficacy in people with hepatitis B Liz Highleyman / 08 December 2016 An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well tolerated but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, ... Nucleic acid polymers reduce HBsAg levels and improve control of hepatitis B virus Liz Highleyman / 27 November 2016 The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen (HBsAg) reduction or clearance when combined with tenofovir and pegylated interferon, according to early results from a small ... Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones Liz Highleyman / 15 November 2016 Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss, according to a report this ... U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection Gilead press release / 11 November 2016 Inexpensive interventions can boost engagement with key stages of viral hepatitis care continuum Michael Carter / 14 October 2016 Several cheap interventions can significantly boost engagement with the continuum of care for viral hepatitis, a systematic literature review and a series of meta-analyses published in The Lancet Infectious Diseases show. Programmes led by ... HBV drug Tyzeka discontinued Healio Hepatology / 11 October 2016 'Step-change in strategy' needed to eliminate HBV as a global health threat Michael Carter / 11 October 2016 Hepatitis B virus (HBV) could be eliminated as a global health threat with a scale-up of vaccination coverage, enhanced efforts to prevent vertical (mother-to-child) transmission and expansion of testing and treatment, according to ... ← Prev1...45678...13Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds